Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
May 04 2016 - 4:45PM
Edgar (US Regulatory)
China Biologic Products,
Inc.
18th Floor, Jialong International
Building
19 Chaoyang Park Road
Chaoyang District, Beijing
100125
People’s Republic
of China
May 4, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
|
Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
|
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran
Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended,
notice is hereby provided that China Biologic Products, Inc. has included disclosure pursuant to such provisions in its Quarterly
Report on Form 10-Q for the quarterly period ended March 31, 2016, which was filed with the U.S. Securities and Exchange Commission
on May 4, 2016. This disclosure can be found under Part II., Item 5. — Other Information.
|
|
|
Very truly yours,
|
|
|
|
/s/
David (Xiaoying) Gao
|
|
David (Xiaoying) Gao
|
|
Chief Executive Officer
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024